Simonelli, L.; Khairkhahan, S.J.; Alessandrino, F.; Montgomery, E.A.; D’Amato, G.
Treatment of Resistant TPM3::ALK + Fusion Protein Metastatic Inflammatory Myofibroblastic Tumor with ALK Targeting and Immune Checkpoint Inhibitor Combined Therapy. Precis. Oncol. 2025, 1, 1.
https://doi.org/10.3390/precisoncol1010001
AMA Style
Simonelli L, Khairkhahan SJ, Alessandrino F, Montgomery EA, D’Amato G.
Treatment of Resistant TPM3::ALK + Fusion Protein Metastatic Inflammatory Myofibroblastic Tumor with ALK Targeting and Immune Checkpoint Inhibitor Combined Therapy. Precision Oncology. 2025; 1(1):1.
https://doi.org/10.3390/precisoncol1010001
Chicago/Turabian Style
Simonelli, Leonardo, Sebastian James Khairkhahan, Francesco Alessandrino, Elizabeth Anne Montgomery, and Gina D’Amato.
2025. "Treatment of Resistant TPM3::ALK + Fusion Protein Metastatic Inflammatory Myofibroblastic Tumor with ALK Targeting and Immune Checkpoint Inhibitor Combined Therapy" Precision Oncology 1, no. 1: 1.
https://doi.org/10.3390/precisoncol1010001
APA Style
Simonelli, L., Khairkhahan, S. J., Alessandrino, F., Montgomery, E. A., & D’Amato, G.
(2025). Treatment of Resistant TPM3::ALK + Fusion Protein Metastatic Inflammatory Myofibroblastic Tumor with ALK Targeting and Immune Checkpoint Inhibitor Combined Therapy. Precision Oncology, 1(1), 1.
https://doi.org/10.3390/precisoncol1010001
